Showcase Companies
Each year, NCI SBIR works with more than 70 third-party investors and strategic partners to select companies to pitch at leading investor events. Below, we present the 39 companies that have been selected for 2023. If you are an investor or a company interested in working with these companies, you can find their technology and contact information below.
Are you interested in joining the review panel for next year’s NCI SBIR Investor Initiatives? Share your information with NCI SBIR Director of Investor Relations, Brittany Connors.
Biopharmaceuticals
-
Accuronix Therapeutics
St. Louis, MO
Small molecule targeting sigma-2 receptor
Bradley T. Keller (bkeller@accuronix.com) -
Allterum Therapeutics
Houston, TX
Anti-CD127 antibody
Atul Varadhachary (atul@fannininnovation.com) -
AVM Biotechnology
Seattle, WA
Novel non-toxic preconditioning regimen for cancer cell therapy
Theresa Deisher (tdeisher@avmbiotech.com) -
BioMimetix
Greenwood Village, CO
Novel therapeutic class of redox-active metalloporphyrin compounds
Rob Hellewell (robert.hellewell@bmxpharma.com) -
Curadel Surgical Innovations
Natick, MA
Theranostic drugs for optical surgical navigation
John V. Frangioni (jvfrangioni@curadel.com) -
Enzyme by Design
Chicago, IL
Novel glutaminase-free mammalian asparaginase with minimized immunogenicity
Amanda Schalk (amanda@enzymebydesign.com) -
Immunophotonics
St. Louis, MO
Pioneering Interventional Immuno-Oncology™
IR@immunophotonics.com -
Indee Labs
Berkeley, CA
Instruments for more effective engineered cell therapies
Ryan Pawell (ryan@indeelabs.com) -
Kuda Therapeutics
Salt Lake City, UT
Novel dual HIF-á inhibitor and inducer of ferroptosis
Mei Koh, Ph.D. (mei.koh@kudatherapeutics.com) -
Luminary Therapeutics
Minneapolis, MN
Novel gamma delta allogenic manufacturing platform
Jeff Liter (j.liter@luminarytx.com) -
Microvascular Therapeutics
Tucson, AZ
CD90-targeted phase shift microbubbles for HIFU-mediated non-thermal ablation of tumors
Emmanuelle Meuillet (e.meuillet@mvtpharma.com) -
Modulation Therapeutics
Morgantown, WV
First-in-class targeted radiotherapies
Lori Hazlehurst (hazlehurst@modulationtherapeutics.com) -
Privo Technologies
Peabody, MA
Nanoparticle-based drug delivery platform
Manijeh Goldberg (mgoldberg@privotechnologies.com) -
Reveal Pharmaceuticals
Cambridge, MA
Gadolinium-free MRI contrast agent
Vera Hoffman (ir@revealpharma.com) -
RNA Nanotherapeutics
Mason, OH
Multifunctional RNA nanoparticles Breast
Xiaoting Zhang (RNANanotherapeutics@gmail.com) -
StemSynergy Therapeutics
Miami, FL
Small molecule modulators of key signaling pathways (WNT, Notch, MYC, Hippo)
Anthony Capobianco (capobianco@stemsynergy.com) -
Stingray Therapeutics
Houston, TX
Potent and selective oral ENPP1 inhibitor
Jonathan P. Northrup (jon@stingraytx.com) -
Talus Bioscience
Seattle, WA
Transcription factor inhibitors for targeted cancer therapeutics
Alex Federation (afederation@talus.bio) -
Ternalys Therapeutics
Chapel Hill, NC
Engineered, non-coding microRNA-based therapy
Kenneth I. Moch (kmoch@ternalys.com) -
Tezcat Biosciences
Avon, CT
Metabolically selective RAS cancer therapeutics
Craig Ramirez (craig@tezcat.co) -
Trace Biosciences
Portland, OR
Nerve-specific imaging agents for surgery
Connor Barth (connor@trace-bio.com) -
TransCode Therapeutics
Boston, MA
Targeted therapy for metastatic cancer
Zdravka Medarova (zdravka.medarova@transcode.therapeutics.com) -
Vivreon Biosciences
San Diego, CA
Oral, gut-restricted therapeutic
Milton Greenberg (milton@vivreonbiosciences.com)
Diagnostics / Tools
-
EarlyDiagnostics
Los Angeles, CA
Blood-based cfDNA multi-cancer test
Xiaohui Ni (xiaohui.ni@earlydx.com) -
Lifegene-Biomarks
San Juan, Puerto Rico
Precision DNA methylation PCR tests in biofluids
Rafael Guerrero-Preston (rguerrero@lifegenedna.com) -
MicrOmics
Spanish Fork, UT
Tool developer for ultra-sensitive proteomics analysis
Ryan Kelly (ryan.kelly@micromicstech.com)
Devices
-
Alpenglow Biosciences
Seattle, WA
AI-enabled 3D spatial biology platform
Nicholas Reder (nick@alpenglowbiosciences.com) -
Ananya Health
San Francisco, CA
Self-contained, portable cryoablation device
Anu Parvatiyar (anu@ananya.health) -
Arsenal Medical
Waltham, MA
Solvent-free, shear-responsive, silicone-based biomaterial
Upma Sharma (usharma@arsenalmedical.com) -
Clarix Imaging
Chicago, IL
Bringing true 3D clarity to specimen imaging
Xiao Han (xiao.han@clariximaging.com) -
Euclid Beamlabs
Beltsville, MD
Electronic brachytherapy device
Darrin Leonhardt (d.leonhardt@euclidtechlabs.com) -
Leuko Labs
Boston, MA
Non-invasive white blood cell monitoring
Carlos Castro-Gonzalez (carlos@leuko.com) -
Navigation Sciences
Brookline, MA
Real-time margin measurement for precision cancer surgery
Alan Lucas (alan.lucas@navigationsci.com) -
NE Scientific
Boston, MA
Intraoperative guidance platform
Andrea Borsic (aborsic@ne-scientific.com) -
Savage Medical
FREMONT, CA
Novel device alternative to temporary diverting ostomies
Dean Hu (dean.hu@savagemed.com) -
TheraBionic
WINSTON-SALEM, NC
Novel, portable, radiowave-delivering therapeutic device
Boris Pasche (boris.pasche@therabionic.com)
Digital Health
-
Envisagenics
New York, NY
Using AI to develop therapies
Maria Luisa Pineda (marialpineda@envisagenics.com) -
Cancer Insights
Bedford Hills, NY
AI platform for clinical decision support
Tarun Kumar (tarun@vizlitics.com) -
XanthosHealth
St. Paul, MN
Social care referral platform
Pinar Karaca-Mandic (pkmandic@xanthoshealth.com)